Judge Profile

John G. New

37 IP cases indexed. Covers patent matters.

Cases Presided Over

37 cases indexed | Page 2 of 2

patent terminated or settled · Mar 25, 2024

Intersect ENT, Inc. et al. v.New Amsterdam, LLC

· IPR2024-00713

Intersect ENT and New Amsterdam settled their IPR dispute over U.S. Patent 6,916,483, filing a joint motion that led the PTAB to terminate the proceeding before trial.

patent instituted · Mar 9, 2024

Avation Medical, Inc. v.EMKinetics, Inc.

· IPR2024-01375

Avation Medical successfully secured the institution of its IPR against EMKinetics, challenging claims 1-13 based on obviousness over combinations of prior art. The Board found that Petitioner adequately supported unpatentability by demonstrating skilled artisans could make the claimed modifications to existing nerve stimulation methods.

patent final · Mar 9, 2024

Avation Medical, Inc. v.EMKinetics, Inc.

· IPR2024-01375

The PTAB found all 13 challenged claims unpatentable under 35 U.S.C § 103. The Board concluded that the claimed nerve stimulation therapy was obvious over combinations of prior art, specifically citing modifications to Svihra and Amarenco using Mann and Ponsford. This decision confirms the lack of inventive step for the technology described in the patent.

patent terminated or settled · Feb 21, 2024

Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.

· IPR2024-00563

Dr. Reddy’s and Eye Therapies settled their IPR dispute, resulting in a joint motion that terminated the proceedings. The Board granted the termination and kept the settlement confidential.

patent instituted · Feb 12, 2024

Formycon AG v.Regeneron Pharmaceuticals, Inc.

· IPR2025-00233

Formycon secured an institution of IPR against Regeneron's VEGF‑antagonist formulation patent (10,464,992), covering claims 1‑18, after the Board found a reasonable likelihood of success.

patent denied · Jan 31, 2024

Dexcom, Inc. v.Abbott Diabetes Care Inc.

· IPR2024-00520

Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.

patent terminated or settled · Jan 24, 2024

Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.

· IPR2024-00467

Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.

Arctic Invent — IP Strategy

Facing a similar IP matter?

Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.

Consult our team →